YEM Search

搜索结果

SLC22A1

靶点ID:TCMBANKGE004817

靶点别名:HOCT1; OCT1; oct1_cds

靶点描述:solute carrier family 22 member 1

染色体:6

染色体位置:6q25.3

靶点类型:protein-coding

HERB_ID:-

HGNC_Link:10963

OMIM_Link:602607

Ensembl_Link:ENSG00000175003

靶点对应的植物

ID	拉丁名	药名	药用植物名	功能与主治	来源	药用部位	使用民族

靶点对应的化合物

化合物ID	化合物名	别名	分子式	分子质量	Smiles

TCMBANKIN000094	choline	Choline chloride; choline hydroxide	C5H14NO+	104.17 g/mol	C[N+](C)(C)CCO
TCMBANKIN014683	Tobacco ene		C9H6Cl6O3S		C1C2C(COS(=O)O1)C3(C(=C(C2(C3(Cl)Cl)Cl)Cl)Cl)Cl
TCMBANKIN016334	(-)-noradrenaline	to_000024; 1,2-Benzenediol, 4-[(1R)-2-amino-1-hydroxyethyl]-; KBio3_001579; CHEBI:18357; NCGC00159406-02; 4-[(1R)-2-Amino-1-hydroxyethyl]-1,2-benzenediol; Levoarterenol; KBio2_006625; KBio1_000230; L-Noradrenaline; NCGC00159406-05; Nor adrenalin (TN); Nor adrenalin; Noradrenaline (JP15); NINDS_000230; 4-[(1R)-2-amino-1-hydroxy-ethyl]pyrocatechol; Spectrum_001009; norepinephrinum; SPECTRUM1500436; KBio2_004057; Spectrum3_000520; KBio2_001489; DivK1c_000230; nchembio705-1; PDSP1_001111; 4-[(1R)-2-amino-1-hydroxy-ethyl]benzene-1,2-diol; 51-41-2; 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-; KBioSS_001489; C00547; NCGC00159406-04; BSPBio_002079; AIDS335520; A7257_SIGMA; KBioGR_000635; D00076; (−)-Norepinephrine; 1,2-Benzenediol, 4-(2-amino-1-hydroxyethyl)-, (R)-(-)-; Spectrum5_001068; Arterenol; Spectrum4_000078; PDSP2_001095; Spectrum2_001064; (-)-(R)-Norepinephrine; SGCUT00123; AIDS-335520; Norepinephrine (INN); SPBio_001048; IDI1_000230	C8H11NO3	169.18	C1=CC(=C(C=C1C(CN)O)O)O
TCMBANKIN017939	α-lindane		C6H6Cl6 or ClCH(CHCl)4CHCl		C1(C(C(C(C(C1Cl)Cl)Cl)Cl)Cl)Cl
TCMBANKIN058114	trans-caffeic acid	3-(3,4-dihydroxy-phenyl)-acrylic acid; caffeic acid; Caffeate; Lopac-C-0625; 71693-97-5; DivK1c_006624; KBio2_007302; (Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; NCGC00015206-02; CAS-3331-39-5; 60020_FLUKA; AI3-63211; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid polymer; (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; NSC623438; 4-(2'-Carboxyvinyl)-1,2-dihydroxybenzene; KBio2_004734; (2Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; CHEMBL1320034; AIDS-002287; AIDS002287; 501-16-6; CHEBI:36281; Prestwick1_000902; KBio1_001568; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid; AKOS000273846; OR1165; SMR000058214; Spectrum2_001612; 3,4-dihydroxycinnamate; (Z)-3-(3,4-dihydroxyphenyl)acrylic acid; Caffeicacid; KOP; AC1NO658; CCRIS 847; Caffeic acid dehydrogenation homopolymer; SPECTRUM1503987; Spectrum4_001694; SCHEMBL3682144; NCGC00017364-01; NCGC00022654-08; 4-(2-Carboxyethenyl)-1,2-dihydroxybenzene; 78734C5A-1281-44D4-B8A0-A3188AD437E3; cis-Caffeic acid; 3-(3,4-dihydroxyphenyl)acrylic acid; Cinnamic acid, 3,4-dihydroxy-; KBioGR_001988; 3,4-Dihydroxybenzeneacrylic acid; 3,4-dihydroxycinnamic acid; trans-caffeic acid; AIDS-026339; NCGC00015206-01; HSDB 7088; ZINC4482687; (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; 3-(3,4-dihydroxyphenyl)prop-2-enoate; Isocaffeic acid; SBB006475; InChI=1/C9H8O4/c10-7-3-1-6(5-8(7)11)2-4-9(12)13/h1-5,10-11H,(H,12,13)/b4-2; NCGC00017364-02; EU-0100208; C01197; MolPort-001-759-162; KBioSS_002166; Caffeic acid pure; caffeic acid ; trans-Caffeate; (2E)-3-(3,4-dihydroxyphenyl)acrylic acid; NSC 57197; (2E)-3-(3,4-Dihydroxyphenyl)-2-propenoic acid; Spectrum_001686; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, (E)-; KBio2_002166; Caffeic acid, cis-; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-; 3,4-Dihydroxybenzeneacrylate; 3-(3,4-Dihydroxy phenyl)-2-propenoic acid; 4361-87-9; 3,4-Dihydroxy-trans-cinnamate; caffeicacid; AR-360/40806927; EINECS 206-361-2; 60018_FLUKA; Caffeic acid polymer; (E)-3-(3,4-dihydroxyphenyl)acrylic acid; NCGC00022654-04; ZX-AL002121; C0625_SIGMA; SDCCGMLS-0002982.P003; 3-(3,4-Dihydroxyphenyl)-2-propenoic acid, homopolymer; SPBio_001643; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)- (9CI); NCGC00017364-03; 3-(3,4-dihydroxyphenyl)prop-2-enoic acid; AC1LU7RL; SPBio_002943; CHEBI:16433; AIDS026339; 2-Propenoic acid, 3-(3,4-dihydroxyphenyl)-, homopolymer; CHEBI:17395; TNP00311; SpecPlus_000528; Prestwick0_000902; MLS000069738; 3,4-dihydroxy-cinnamic acid; 3-(3,4-Dihydroxyphenyl)propenoic acid; NCI60_004400; NSC57197; Caffeic; Lopac-C-0625; NCGC00015206-01; Caffeic acid; cis-Caffeic acid; NCGC00017364-01; (Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; C01481; 331-39-5; NCGC00015206-02; CAS-3331-39-5; 3,4-Dihydroxycinnamic acid; CHEBI:17395; (2Z)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid; TNP00311; (Z)-3-(3,4-dihydroxyphenyl)acrylic acid; Caffeate; 1- coffee acid	C9H8O4	180.16 g/mol	C1=CC(=C(C=C1C=CC(=O)O)O)O
TCMBANKIN060910	cis-9-hexadecenoic acid		C16H30O2	254.41 g/mol	CCCCCCC=CCCCCCCCC(=O)O
TCMBANKIN061038	Gaidic acid		C16H30O2	254.41 g/mol	CCCCCCCCCCCCCC=CC(=O)O

靶点对应的疾病

疾病ID	疾病名	MeSH名	HPO名	UMLS名	疾病类型

TCMBANKDI000061	Digestive System Diseases; Neoplasms	Abnormality of the digestive system; Neoplasm	Neoplastic Process	group
TCMBANKDI000771	Skin and Connective Tissue Diseases	Abnormality of the integument; Abnormality of the immune system	Sign or Symptom	phenotype
TCMBANKDI002231	Digestive System Diseases	Abnormality of the digestive system	Disease or Syndrome	disease
TCMBANKDI002512	Digestive System Diseases	Abnormality of the digestive system; Abnormality of the immune system	Disease or Syndrome	disease
TCMBANKDI002557	Eye Diseases; Skin and Connective Tissue Diseases; Musculoskeletal Diseases; Immune System Diseases; Stomatognathic Diseases	-	Disease or Syndrome	disease
TCMBANKDI003248	Nutritional and Metabolic Diseases; Endocrine System Diseases	Abnormality of metabolism/homeostasis; Abnormality of the endocrine system	Disease or Syndrome	disease
TCMBANKDI004039	Infections	-	Disease or Syndrome	disease
TCMBANKDI004086	Nutritional and Metabolic Diseases	Abnormality of metabolism/homeostasis	Disease or Syndrome	disease
TCMBANKDI004958	Neoplasms; Hemic and Lymphatic Diseases	-	Neoplastic Process	disease
TCMBANKDI007618	Hemic and Lymphatic Diseases	Abnormality of blood and blood-forming tissues	Disease or Syndrome	phenotype
TCMBANKDI009231	Pathological Conditions, Signs and Symptoms; Infections	Abnormality of the immune system	Disease or Syndrome	disease
TCMBANKDI016096	Pathological Conditions, Signs and Symptoms; Eye Diseases; Nervous System Diseases	Abnormality of the eye	Disease or Syndrome	disease
TCMBANKDI016890	Digestive System Diseases; Neoplasms	-	Neoplastic Process	disease
TCMBANKDI017642	Neoplasms	Abnormality of the integument; Neoplasm	Neoplastic Process	disease
TCMBANKDI020603	Pathological Conditions, Signs and Symptoms	-	Anatomical Abnormality	phenotype
TCMBANKDI020634	Nutritional and Metabolic Diseases	Abnormality of metabolism/homeostasis	Disease or Syndrome	disease
TCMBANKDI020942	-	-	Laboratory Procedure	phenotype
TCMBANKDI023464	Nervous System Diseases	Abnormality of the nervous system	Disease or Syndrome	disease
TCMBANKDI024262	-	-	Neoplastic Process	phenotype
TCMBANKDI024535	Neoplasms; Respiratory Tract Diseases	Neoplasm; Abnormality of the respiratory system	Neoplastic Process	disease
TCMBANKDI025420	Digestive System Diseases; Neoplasms	Abnormality of the digestive system; Neoplasm	Neoplastic Process	disease
TCMBANKDI025502	-	-	Laboratory Procedure	phenotype
TCMBANKDI027131	Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases	-	Disease or Syndrome	disease
TCMBANKDI027289	Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Behavior and Behavior Mechanisms	-	Mental or Behavioral Dysfunction	disease
TCMBANKDI029861	Neoplasms; Hemic and Lymphatic Diseases	-	Neoplastic Process	disease
TCMBANKDI030540	Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases	Abnormality of the genitourinary system; Neoplasm	Neoplastic Process	disease
TCMBANKDI031192	Neoplasms; Male Urogenital Diseases	-	Neoplastic Process	disease
TCMBANKDI031381	Neoplasms; Hemic and Lymphatic Diseases	-	Neoplastic Process	disease
TCMBANKDI031523	Hemic and Lymphatic Diseases	Abnormality of blood and blood-forming tissues	Disease or Syndrome	disease